Obsidian Therapeutics (OBX) – Investment Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Obsidian Therapeutics (NASDAQ: OBX):

• 9/27/2026 – Obsidian Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/23/2026 – Obsidian Therapeutics was upgraded by William Blair to “strong-buy”.
• 9/22/2026 – Obsidian Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $32.00 price target on the stock.
• 9/19/2026 – Obsidian Therapeutics was upgraded by Wall Street Zen to “sell”.
• 9/9/2026 – Obsidian Therapeutics is now covered by William Blair. They set an “outperform” rating on the stock.
• 9/2/2026 – Obsidian Therapeutics is now covered by Weiss Ratings. They set a “sell (d-)” rating on the stock.
• 8/18/2026 – Obsidian Therapeutics is now covered by Lifesci Capital. They set an “outperform” rating and a $43.00 price target on the stock.
• 8/6/2026 – Obsidian Therapeutics is now covered by TD Cowen. They set a “buy” rating on the stock.
• 8/6/2026 – Obsidian Therapeutics was upgraded by Zacks Research to “hold”.
• 8/5/2026 – Obsidian Therapeutics is now covered by Piper Sandler. They set an “overweight” rating and a $42.00 price target on the stock.

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.